QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
This is a randomized phase 2 study to compare the efficacy of neoadjuvant, consolidation, and adjuvant immunotherapy (NANT NSCLC Combination Immunotherapy; experimental arm) to standard of care (surgery and adjuvant chemotherapy; control arm) in subjects with stage II-IIIa resectable NSCLC.
Non Small Cell Lung Cancer
DRUG: Nab-paclitaxel|DRUG: Cisplatin|DRUG: 5Fluorouracil|DRUG: Cyclophosphamide|BIOLOGICAL: ETBX-011|BIOLOGICAL: ETBX-051|BIOLOGICAL: ETBX-061|BIOLOGICAL: GI-4000|BIOLOGICAL: GI-6301|DRUG: Aldoxorubicin|DRUG: Avelumab|DRUG: ALT-803|BIOLOGICAL: haNK|DRUG: Docetaxel|DRUG: carboplatin
Relapse-free survival ( RFS), time from the date of randomization to the date of first radiographically determined new lesion by RECIST Version 1.1 based on BICR or date of death (by any cause), whichever occurs first, 18 months
This is a randomized phase 2 study to compare the efficacy of neoadjuvant, consolidation, and adjuvant immunotherapy (NANT NSCLC Combination Immunotherapy; experimental arm) to standard of care (surgery and adjuvant chemotherapy; control arm) in subjects with stage II-IIIa resectable NSCLC.